Cost-effectiveness of Population-Wide Genomic Screening for Hereditary Breast and Ovarian Cancer in the United States
- 1 October 2020
- journal article
- research article
- Published by American Medical Association (AMA) in JAMA Network Open
- Vol. 3 (10) , e2022874
Abstract
Hereditary breast and ovarian cancer (HBOC) genetic variants, particularly in the BRCA1 (OMIM 113705) and BRCA2 (OMIM 600185) genes, confer increased lifetime risk of developing cancer in women.1 Knowledge of HBOC variants empowers women to choose more intensive precancer screening practices, including magnetic resonance imaging (MRI) to detect cancer sooner, and for some to undergo chemoprevention and/or prophylactic risk-reducing mastectomy (RRM) and/or risk-reducing salpingo-oophorectomy (RRSO), which lower cancer risk and mortality.2,3Keywords
This publication has 34 references indexed in Scilit:
- American Society of Clinical Oncology Policy Statement Update: Genetic and Genomic Testing for Cancer SusceptibilityJournal of Clinical Oncology, 2015
- Use of risk-reducing surgeries in a prospective cohort of 1,499 BRCA1 and BRCA2 mutation carriersBreast Cancer Research and Treatment, 2014
- Population-Based Screening forBRCA1andBRCA2JAMA, 2014
- Population-based screening for breast and ovarian cancer risk due toBRCA1andBRCA2Proceedings of the National Academy of Sciences, 2014
- MRI breast screening in high-risk women: cancer detection and survival analysisBreast Cancer Research and Treatment, 2014
- Health-state utility values in breast cancerExpert Review of Pharmacoeconomics & Outcomes Research, 2010
- Association of Risk-Reducing Surgery in BRCA1 or BRCA2 Mutation Carriers With Cancer Risk and MortalityJAMA, 2010
- Comparative effectiveness of screening and prevention strategies among BRCA1/2-affected mutation carriersBreast Cancer Research and Treatment, 2010
- Determination of quality of life-related utilities for health states relevant to ovarian cancer diagnosis and treatmentGynecologic Oncology, 2009
- Mortality after bilateral salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers: a prospective cohort studyThe Lancet Oncology, 2006